[Value of vasodilator treatment in beginning cardiac insufficiency].
Two cooperative studies, from the Veterans Administration in 1986 and the Consensus Study in 1987 clearly assessed the beneficial prognostic effect of vasodilator therapy in congestive heart failure. Nevertheless, the results obtained are still limited, and the mortality rate remains at about 36% at 1 year under enalapril therapy. Experimental, hemodynamic and clinical data have proved the value of early vasodilator administration, especially of an angiotensin-converting enzyme inhibitor in congestive heart failure of new onset or asymptomatic. Inhibition of the renin-angiotensin-aldosterone system and decrease in catecholamines improve left ventricular function and increase survival.
Vacheron
A
A
D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents
Intérêt du traitement vasodilatateur au cours de l'insuffisance cardiaque débutante.